ATRA Atara Biotherapeutics Inc: Forward P/S Multiple
Atara Biotherapeutics (ATRA) strives for global leadership in immunopharmacy through the development of its T-cell platform. On GURU.Markets, the projected price-to-sales ratio demonstrates market expectations, where 20.30 serves as the current parameter value. The uniqueness of the donor method provides the issuer with significant pricing power, while a focus on retaining leading scientists and regulatory experts ensures the stability of the R&D core.
Comprehensive metric breakdowns and analytics for atarabio.com (ATRA)
- current price and projected stock value:
- company stock capitalization data:
- issuer book value statistics:
- issuer credit burden and liquidity indicators:
- net income and valuation multiples indicators:
ATRA - Net Financial Result|Expected Profit Atara Biotherapeutics|ATRA - Market Cap to Earnings|Projected Price to Earnings Atara Bio|ATRA - Company Value to Earnings Growth Ratio|EV/EBITDA Multiple ATRA|ATRA - Income before deduction of interest, taxes and amortization|Net earnings per share (EPS TTM) Atara Biotherapeutics|ATRA - Net earnings per one share for the last twelve months|Year-over-year earnings per share growth for the last twelve months atarabio.com|ATRA - Earnings per share increase in current year|Earnings growth forecast for next year Atara Biotherapeutics
- issuer revenue and sales details:
Fundamental company analysis:Atara Biotherapeutics Inc (ATRA)
This ratio compares the current market value of Atara Biotherapeutics (ATRA) with expected annual revenues, measuring the premium investors are willing to pay per unit of future revenue. By analyzing the forward P/S valuation, the market assesses the growth potential of the company, whose R&D expenses and cash flow have been stabilized through strategic alliances with European pharmaceutical corporations and royalties.
Key competitors
Forward P/S Multiple ARGX (argenx)|BioNTech Inc. (BNTX) - Market Cap to Future Revenue Ratio|Abivax Corp - Forward P/S Multiple|ADMA - Forward P/S Multiple|PTGX (Protagonist Therapeutics) - Forward Price-to-Revenue Multiple|IMVT: Price to Expected Revenue Ratio|KNSA (Kiniksa) - Forward P/S Multiple|Forward P/S Multiple Grifols SA|Price-to-Projected Revenue Ratio Adaptive Biotechnologies Corp (ADPT)|CLDX (Celldex Corp) - Forward Price to Sales|Forward P/S Multiple AUPH (Aurinia Pharmaceuticals)|Forward P/S Multiple biocryst.com BCRX|VERA: Forward Price-to-Revenue Multiple|Forward Price to Sales DNTH (Dianthus Therapeutics Inc)|PHVS: Forward P/S Multiple|ABCL (AbCellera Corp) - Price-to-Projected Revenue Ratio|TRML (Tourmaline Bio, Inc.) - Forward P/S Multiple|precigen.com (PGEN) - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio Pharming Group (PHAR)|NKTR - Market Cap to Future Revenue Ratio|Upstream Bio Corp - Forward Price-to-Revenue Multiple|Price to Expected Revenue Ratio ZBIO (Zenas Corp)|Immunome, Inc. - Forward P/S Multiple|Forward Price to Sales GOSS (gossamerbio.com)|KALV: Forward P/S Multiple|Market Cap to Future Revenue Ratio Septerna, Inc. (SEPN)|Price-to-Projected Revenue Ratio Pieris Pharmaceuticals Inc|SVRA: Forward Price to Sales|Forward P/S Multiple RIGL|Forward P/S Multiple anaptysbio.com (ANAB)|Price-to-Projected Revenue Ratio Astria Therapeutics, Inc. ATXS|ENGN (enGene Holdings Inc) - Future Price to Revenue|RAPT Therapeutics, Inc. - Forward P/S Multiple|Market Cap to Future Revenue Ratio Aerovate Therapeutics Inc|ACRS (Aclaris Therapeutics) - Forward Price-to-Revenue Multiple|kyvernatx.com (KYTX) - Forward P/S Multiple|Forward Price-to-Revenue Multiple TLSA|CABA (Cabaletta Bio Inc.) - Price to Expected Revenue Ratio|Forward P/S Multiple VTYX|Market Cap to Expected Sales Ratio Theratechnologies, Inc|Forward P/S Multiple AVTX (Avalo Therapeutics, Inc)|ELDN - Forward Price-to-Revenue Multiple|AGEN - Price-to-Projected Revenue Ratio|Market Cap to Expected Sales Ratio Climb Bio Inc. CLYM|ZURA: Forward P/S Multiple|aTyr Pharmaceuticals (ATYR) - Forward P/S Multiple|Forward Price-to-Revenue Multiple ADAG|IMA (Ikena Oncology, Inc.) - Price to Expected Revenue Ratio|Price-to-Projected Revenue Ratio Shattuck Labs, Inc. (STTK)|EQ (equilliumbio.com) - Forward Price to Sales|Forward P/S Multiple CNTB (Connect Biopharma Holdings Limited)|Forward P/S Multiple Immunic Therapeutics IMUX|IFRX - Price-to-Projected Revenue Ratio|Future Price to Revenue XFOR|ACET: Forward P/S Multiple|Celularity - Forward Price to Sales|INMB (INmune Bio Corp) - Forward P/S Multiple|Forward P/S Multiple Barinthus Biotherapeutics Corp|Price-to-Projected Revenue Ratio Kezar Life Sciences (KZR)|SABS (sabbiotherapeutics.com) - Forward Price to Sales|Price-to-Projected Revenue Ratio Akari Therapeutics Plc AKTX|ENLV - Forward Price-to-Revenue Multiple|Q32 Bio Corp - Forward P/S Multiple|GOVX - Forward P/S Multiple|EDSA (Edesa Biotech, Inc.) - Forward Price-to-Revenue Multiple|ibioinc.com - Forward Price to Sales|CARM (Carisma Therapeutics Inc) - Forward P/S Multiple|XTL Biopharmaceuticals Ltd (XTLB) - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio Bolt Biotherapeutics (BOLT)|Forward Price-to-Revenue Multiple hcwbiologics.com HCWB|Price-to-Projected Revenue Ratio Aptevo Therapeutics Inc. APVO|AIM - Forward Price-to-Revenue Multiple|ADTX: Forward Price-to-Revenue Multiple|GRI - Forward P/S Multiple|XORTX (XRTX) - Price-to-Projected Revenue Ratio|Market Cap to Projected Revenue HIND|REVB (Revelation Biosciences) - Forward P/S Multiple|Market Cap to Future Revenue Ratio indaptusrx.com INDP|Forward P/S Multiple SCNI|Forward P/S Multiple calcimedica.com (CALI)|Affimed N.V. - Forward Price-to-Revenue Multiple|Price to Expected Revenue Ratio ALLK (Allakos Inc)|HOOKIPA - Forward P/S Multiple|IGMS - Forward P/S Multiple|iTeos Therapeutics, Inc. (ITOS) - Price-to-Projected Revenue Ratio|Ocean Biomedical Inc - Forward Price to Sales|TCBP (TC BioPharm (Holdings) PLC) - Forward P/S Multiple|Forward P/S Multiple Third Harmonic Bio Inc
